



eLife's transparent reporting form

We encourage authors to provide detailed information *within their submission* to facilitate the interpretation and replication of experiments. Authors can upload supporting documentation to indicate the use of appropriate reporting guidelines for health-related research (see [EQUATOR Network](#)), life science research (see the [BioSharing Information Resource](#)), or the [ARRIVE guidelines](#) for reporting work involving animal research. Where applicable, authors should refer to any relevant reporting standards documents in this form.

If you have any questions, please consult our Journal Policies and/or contact us: editorial@elifesciences.org.

Sample-size estimation

- You should state whether an appropriate sample size was computed when the study was being designed
- You should state the statistical method of sample size computation and any required assumptions
- If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Power calculations weren't performed for the GWAS, since the UK Biobank was a preexisting study with a fixed sample size. However, outcomes for phenome-wide analyses were excluded if there weren't enough cases to be well-powered as described in the Methods on page 22.

Replicates

- You should report how often each experiment was performed
- You should include a definition of biological versus technical replication
- The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates
- If you encountered any outliers, you should describe how these were handled
- Criteria for exclusion/inclusion of data should be clearly stated
- High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

A flowchart of the study design is provided in Figure 1.
Inclusion/exclusion criteria for GWAS, handling of outliers for biochemical measurements, and other relevant assay characteristics are provided in the Methods (page 18-19).
Definition of outcomes for MR analyses is provided in the Methods (page 21-23) with additional details in Supplementary File 1 – Table 1 and 2.



Statistical reporting

- Statistical analysis methods should be described and justified
- Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10)
- For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d)
- Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Description of statistical analyses are presented for GWAS in the Methods (page 20) and for MR analyses in the Methods (pages 23-24). Significant MR analyses are presented visually in Figure 3 – Figure Supplements 1 to 6. P-values and summary statistics are reported for all MR analyses in Supplementary File 1 - Tables 5 to 10, 12, and 13.

(For large datasets, or papers with a very large number of statistical tests, you may upload a single table file with tests, Ns, etc., with reference to sections in the manuscript.)

Group allocation

- Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied
- Indicate if masking was used during group allocation, data collection and/or data analysis

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Not applicable. In this study design, investigators did not allocate participants to groups.

Additional data files (“source data”)

- We encourage you to upload relevant additional data files, such as numerical data that are represented as a graph in a figure, or as a summary table
- Where provided, these should be in the most useful format, and they can be uploaded as “Source data” files linked to a main figure or table
- Include model definition files including the full list of parameters used
- Include code used for data analysis (e.g., R, MatLab)
- Avoid stating that data files are “available upon request”

Please indicate the figures or tables for which source data files have been provided:



eLIFE

Westbrook Centre, Milton Road

Cambridge CB4 1YG

UK

P 01223 855340

W elifesciences.org

T @elife

All MR results and genome-wide significant SNPs have been provided in the Supplementary File 1 - Tables 4 to 13.

Individual-level data cannot be provided, but it is available to all researchers by application to the UK Biobank. Summary-level GWAS data will be returned to the UK Biobank Access Team for use by other researchers.

Code will be uploaded to GitHub after removing any sensitive or identifiable information (<https://github.com/GMELab>).